In a bid to bolster its inflammatory bowel disease (IBD) portfolio, AbbVie has agreed to acquire all the outstanding equity of Celsius Therapeutics. Through the deal, which is worth up to US$250 M, AbbVie will gain access to Celsius’ investigational asset CEL383, which has completed Phase I clinical studies for the treatment of IBD. Interestingly, the acquisition comes only three months after AbbVie announced the acquisition of Landos Biopharma and its portfolio of inflammatory and autoimmune diseases medicines.